Previous 10 | Next 10 |
Indie Semiconductor (INDI -5.4%) shares plummets after the company disclosed a sale of shares by CFO Thomas Schiller. Thomas Schiller sold 200,00 shares of the company's common stock at $11.85 for $2.4M. Form 4 A look at INDI's ownership composition: For further details see: I...
ALX Oncology (ALXO -6.6%) shares plummets after the company disclosed a sale of shares by director Jason Lettmann. Lettmann sold 387,345 shares of the company's common stock at $25.01 - $30.29 in a series of transactions, worth ~$75M. Form 4 A look at ALXO's ownership composition: A...
The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology (ALXO) Presents At 63rd Annual Meeting of ASH - Slideshow
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia PR Newswire CUPERTINO, Calif. , Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its boar...
ALX Oncology (ALXO -25.1%) shares have plunged after the company disclosed a sale of shares by director Jason Lettmann. Lettmann sold 145,637 shares of the company's common stock at $30.12 - $33.92 in a series of transactions, worth ~$4.7M. Form 4 A look at ALXO's ownership composition: Learn...
Gainers: Nuverra Environmental Solutions (NYSE:NES) +88%. Arena (NASDAQ:ARNA) +82%. BELLUS (NASDAQ:BLU) +56%. Foghorn Therapeutics (NASDAQ:FHTX) +43%. Petros Pharmaceuticals (NASDAQ:PTPI) +45%. Biofrontera (NASDAQ:BFRI) +29%. Mawson Infrastructure Group (OTCQB:MIGI) +17%. Reliance Global Grou...
Gainers: Arena Pharmaceuticals (NASDAQ:ARNA) +84%, BELLUS Health (NASDAQ:BLU) +68%, Foghorn Therapeutics (NASDAQ:FHTX) +37%, Petros Pharmaceuticals (NASDAQ:PTPI) +27%, Tabula Rasa HealthCare (NASDAQ:TRHC) +23%. Losers: IGM Biosciences (NASDAQ:IGMS)...
-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS -- Objective responses were observed in patients with relapsed/refractory MDS that had progressed after pr...
ALX Oncology is developing a novel CD47 inhibitor and has differentiated itself from its competitors with its approach. Recent data updates have reaffirmed my original thoughts of their likelihood of success in several indications. I was previously neutral on ALX Oncology, given t...
The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology Holdings (ALXO) Investor Presentation
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...